Apogee Therapeutics Reports Strong 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis

summarizeSummary

Apogee Therapeutics announced highly positive 52-week maintenance data from its Phase 2 APEX clinical trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. The data demonstrated durable maintenance and deepening of efficacy across all lesion and itch endpoints with significantly less frequent dosing (every 3- and 6-months) compared to current standards. This strong profile, combined with a favorable safety record, significantly de-risks the lead candidate and supports the company's plan to initiate Phase 3 trials in the second half of 2026, targeting a potential $50 billion market. Investors should monitor the upcoming Part B data and the progression to Phase 3.

check_boxKey Events

• Positive 52-Week Phase 2 Data

  Zumilokibart (APG777) demonstrated durable maintenance and deepening of efficacy in moderate-to-severe atopic dermatitis with every 3- and 6-month dosing.

• Strong Efficacy Metrics

  The trial achieved 75-85% EASI-75 maintenance, 78-86% vIGA 0/1 maintenance, and significant reductions in Itch NRS, with deepening responses across all endpoints.

• Favorable Safety Profile

  Zumilokibart was well-tolerated across the full 52-week study, with a safety profile generally consistent with other agents in its class, and a low serious TEAE rate of 0.8%.

• Advancing to Phase 3

  The company plans to initiate Phase 3 trials for zumilokibart in atopic dermatitis in the second half of 2026, enabling a potential commercial launch in 2029 for a market estimated at $50 billion.

auto_awesomeAnalysis

Apogee Therapeutics announced highly positive 52-week maintenance data from its Phase 2 APEX clinical trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. The data demonstrated durable maintenance and deepening of efficacy across all lesion and itch endpoints with significantly less frequent dosing (every 3- and 6-months) compared to current standards. This strong profile, combined with a favorable safety record, significantly de-risks the lead candidate and supports the company's plan to initiate Phase 3 trials in the second half of 2026, targeting a potential $50 billion market. Investors should monitor the upcoming Part B data and the progression to Phase 3.